Ann: Successful Completion of Entitlement Offer, page-94

Agree 100%.
My laymans understanding is that biomarkers will be a forward indicator of DMOAD. Won't be definitive one way or the other, more a shade of grey and dependent on more data collection - the commentary could be dialled up or down by the company as it will be subjective, so that will be interesting in itself.
The 002 lookthrough has been flagged right from the beginning in an interiew PR did ages ago. Those secondaries were deliberately put in for that reason. What is encouraging is that the company has had 56 day WOMAC data for >half the participants for ages now (all the first cohort of 30 and a fair chunk of the second 30). Several times now they have stated they WILL be releasing 56 day WOMAC (002 lookthrough) as part of the topline 008. If the results werent at least somewhat good, you would think they would not build anticipation around this and instead bury it deep in the topline or perhaps even omit altogether?